Journalartikel

Jahr der Veröffentlichung: 2014

Seiten: 370-374

Zeitschrift: Aktuelle Rheumatologie

Bandnummer: 39

Heftnummer: 6

ISSN: 0341-051X

eISSN: 1438-9940

DOI Link: https://doi.org/10.1055/s-0034-1385942

Verlag: Georg Thieme Verlag

Abstract: 
The aim of this study was to analyse the effects of a tocilizumab (TOZ) therapy, an anti-IL-6 receptor antibody, on bone mineral density, markers of bone metabolism, parameters of disease activity and function in active rheumatoid arthritis (RA) with inadequate response to tumour necrosis factor inhibition. 37 patients were included in the study, 15 of them terminated the study prematurely because of side effects/persistent infections (9), pregnancy (1), allergic reaction (3), change of residence (2). Finally, 22 patients with active RA could be evaluated (16 females and 6 males, average age 62 years, average disease duration 11 years). 19 patients received a combination medication with TOZ (8 mg/kg BW every 4 weeks) and methotrexate (average dose 15 mg/week) and 3 patients a monotherapy with TOZ because of MTX intolerance. All patients were on prednisolone >= 10 mg/day prior to initiation of the trial. The following outcome parameters were determined at baseline and after 1 year under TOZ therapy: bone mineral density (DXA; right total hip and lumbar spine), markers of bone metabolism (osteocalcin, N-terminal telopeptide of type I collagen - NTx), C-reactive protein und erythrocyte sedimentation rate (ESR), Disease Activity Score 28 (DAS28), Health Assessment Questionnaire (HAQ), and function questionnaire Hannover (FFbH). The bone mineral density of the lumbar spine showed a tendency to increase, whereas the total hip showed constant values. The bone markers showed a significant increase of osteocalcin (P < 0.021), and a tendency of decreased NTx as a resorption marker (P < 0.054). The acute phase reactants (ESR, CRP) showed the expected decline. Furthermore, there was a significant improvement of the DAS28 (P < 0.0001), whereas HAQ and FFbH remained constant. The 1-year TOZ therapy, in mono-as well as in combination therapy with MTX, resulted in osteoprotective effects and a decrease in disease activity in patients with RA and an inadequate response to TNF-alpha inhibition.

Harvard-Zitierstil: Wettich, T., Mueller-Ladner, U., Dischereit, G. and Lange, U. (2014) Effects of Tocilizumab Therapy on Bone Mineral Density, Markers of Bone Metabolism and Disease Activity in TNF-α Inadequate Responders with Active Rheumatoid Arthritis, Aktuelle Rheumatologie, 39(6), pp. 370-374. https://doi.org/10.1055/s-0034-1385942

APA-Zitierstil: Wettich, T., Mueller-Ladner, U., Dischereit, G., & Lange, U. (2014). Effects of Tocilizumab Therapy on Bone Mineral Density, Markers of Bone Metabolism and Disease Activity in TNF-α Inadequate Responders with Active Rheumatoid Arthritis. Aktuelle Rheumatologie. 39(6), 370-374. https://doi.org/10.1055/s-0034-1385942